Urology Times 50 Innovations Series: β3 agonists for overactive bladder

Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Ekene A. Enemchukwu, MD, MPH, discusses the development of β3 agonists for the treatment of overactive bladder (OAB). Enemchukwu is an assistant professor of urology and, by courtesy, of obstetrics and gynecology and medical director of the Stanford Pelvic Health Center, Stanford University, Palo Alto, California